Reunion Neuroscience Inc T.REUN

Healthcare Biotechnology

Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company’s products include RE104 and RE200. The Company’s lead asset, RE-104, which is a psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. The RE104 as a potentially fast-acting treatment for the key indications of postpartum and treatment resistant depression. The Company is developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psych activity for potential use in more chronic treatment paradigms and indications. The Company is focused on the research and development of its RE200 molecule group.

TSX:REUN - Post by User

Reunion Neuroscience Inc

<< Previous

Bullboard Posts

Next >>

Post by AwareInvestoron Apr 29, 2022 8:02am

634 Views

Post# 34641478

Field Trip Health To Divide Into Two Separate Firms

Field Trip Health is set to be split into two separate firms. The company last night indicated that its board has approved an arrangement whereby the firms current operations will split into two separate public companies, one of which is focused on health clinics while the other is focused on next generation drug discovery.

https://thedeepdive.ca/field-trip-health-to-divide-into-two-separate-firms/

<< Previous

Bullboard Posts

Next >>

Cyberattack will leave lasting reputational damage to London Drugs